Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2601 - Profile of individuals who never undergo colorectal cancer screening

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Jérôme Viguier

Authors

J. Viguier1, J.F. Morère2, S. Couraud3, M. Roupret4, C. Touboul5, C. Lhomel6, L. Greillier7, T. de La Motte Rouge8, F. Eisinger9

Author affiliations

  • 1 Ccdc 37, Hôpital Bretonneau, 37044 - Tours/FR
  • 2 Medical Oncology Department, AP-HP, Hôpital Paul Brousse, 94800 - Villejuif/FR
  • 3 Department Of Respiratory Diseases And Thoracic Oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 4 Medical Oncology, Hôpital Universitaire Pitié-Salpêtrière, 75013 - Paris/FR
  • 5 Statistics, Kantar Health, 75014 - Paris/FR
  • 6 Medical, Roche, 9265000 - Boulogne-Billancourt/FR
  • 7 Department Of Multidisciplinary Oncology And Therapeutic Innovations, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, 13009 - Marseille/FR
  • 8 Département D'oncologie Médicale, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 9 Département D'anticipation Et De Suivi Du Cancer Dasc, Institute Paoli Calmettes, 13274 - Marseille/FR
More

Resources

Abstract 2601

Background

Colorectal cancer (CRC) screening has been part of a nationally organized program in France since 2009. In 2015, a fecal immunochemical test (FIT) replaced the previously used guaiac test. Nevertheless, the target participation rate has still not been reached. In this context, it is important to have a clear insight into the characteristics of individuals who remain refractory to screening.

Methods

The French nationwide observational survey EDIFICE 6 was conducted online from 26 June to 28 July 2017 on 12 046 individuals (age, 18-69 years). Representativeness was ensured by quota sampling on age, gender, profession, and stratification by geographical area and type of urban district. Multivariate stepwise logistic regression analysis was conducted to identify factors likely to explain non-uptake of CRC screening. The present analysis focused on the 4300 individuals (age, 50-69 years) with no history of cancer.

Results

Of those who were in the target population for CRC screening, 38% (N = 1625) had never taken part in the CRC screening program. Compared to individuals who had undergone at least one screening test in their life time, those who had never been screened were more likely to be younger (58±6 yrs vs 60±6 yrs, P<0.05), current smokers (30% vs 21%, P<0.05) or socially vulnerable (47% vs 36%, P<0.05). In multivariate analysis, items associated with not undergoing screening included belonging to the socio-professional category of skilled manual workers and supervisory or clerical workers (OR=1.83, 95% CI [1.24 – 2.70]), considering that prevention does not provide effective protection from CRC (OR=1.76 [1.48–2.08]), being a current smoker (OR=1.45 [1.25–1.69]) and being socially vulnerable (OR=1.29, [1.13-1.47]). The most frequently cited reasons for not being screened were "I don't feel concerned" (37%), “individual negligence/not a priority” (32%), fear of the examination/results (29%), and a reason related to the physician (i.e., he didn't suggest screening) (23%).

Conclusions

Medical skepticism for CRC prevention efficiency and vulnerability are social indicators of non-participation in a CRC screening program. Likewise, current smoking—which is already acknowledged as a behavioral risk factor for CRC—is also an indicator of non-uptake of CRC screening.

Clinical trial identification

Editorial Acknowledgement

Medical writing assistance was provided by Potentiel d’Action (France)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings